GlassScriptPhysician profile
Stefan K Young
NPI 1336219211
$3,906.21
in general payments reported to CMS, 2019-2025
11 companies · $722 in 2025
The $722 reported for 2025 was more than what 86% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $163 · 2022: $376 · 2023: $1,986 · 2024: $660 · 2025: $722.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,149 · Travel and Lodging: $1,085 · Entertainment: $133.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,148.62 |
| Travel and Lodging | $1,085.10 |
| Entertainment | $133.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Vision Care, INC. | $1,702.85 | 2022-2025 | Acuvue |
| Coopervision INC. | $571.11 | 2022-2025 | Myday Contact Lens, Misight Contact Lens, Clariti Contact Lens |
| Alcon Vision LLC | $505.94 | 2019-2025 | Dailies Total1, Total30, Precision 1 |
| Sun Pharmaceutical Industries INC. | $345.91 | 2023-2024 | Cequa |
| Sight Sciences, INC. | $157.75 | 2022-2024 | Omni Surgical System |
| Optos, INC. | $133.14 | 2024 | Panoramic Ophthalmoscope, Oct Ophthalmoscope, Nfc-700 |
| Kala Pharmaceuticals, INC. | $125.00 | 2022 | |
| Dompe US, INC. | $121.81 | 2023 | Oxervate |
| Harrow Eye, LLC | $113.51 | 2025 | Vevye |
| Rxsight INC | $66.91 | 2024 | Light Adjustable Lens (Lal), Rxsight Injector Handpiece, Rxsight Light Delivery Device (Ldd) |
| Allergan, INC. | $62.28 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stefan Young listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.